相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3)
Markus Moehler et al.
INTERNATIONAL JOURNAL OF CANCER (2022)
The randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13).
Akihito Tsuji et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Tumor-size responses to first-line is a predictor of overall survival in metastatic colorectal cancer
Lola-Jade Palmieri et al.
EUROPEAN RADIOLOGY (2019)
Early tumor shrinkage after first-line medical treatment of metastatic colorectal cancer: a meta-analysis
Giuseppe A. Colloca et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2019)
Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials
Julien Taieb et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2018)
CT attenuation of liver metastases before targeted therapy is a prognostic factor of overall survival in colorectal cancer patients. Results from the randomised, open-label FIRE-3/AIO KRK0306 trial
Matthias F. Froelich et al.
EUROPEAN RADIOLOGY (2018)
Towards volumetric thresholds in RECIST 1.1: Therapeutic response assessment in hepatic metastases
Katharina S. Winter et al.
EUROPEAN RADIOLOGY (2018)
Automatic segmentation of liver tumors from multiphase contrast-enhanced CT images based on FCNs
Changjian Sun et al.
ARTIFICIAL INTELLIGENCE IN MEDICINE (2017)
Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials
Yu Sunakawa et al.
CLINICAL COLORECTAL CANCER (2017)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2016)
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
Sebastian Stintzing et al.
LANCET ONCOLOGY (2016)
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest
C. Cremolini et al.
ANNALS OF ONCOLOGY (2015)
Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: A systematic review and pooled-analysis
Fausto Petrelli et al.
EUROPEAN JOURNAL OF CANCER (2015)
Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC)
Volker Heinemann et al.
EUROPEAN JOURNAL OF CANCER (2015)
Progression-Free Survival: Helpful Biomarker or Clinically Meaningless End Point?
Alan P. Venook et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials
Giuseppe Aprile et al.
ONCOTARGET (2015)
Comparing two correlated C indices with right-censored survival outcome: a one-shot nonparametric approach
Le Kang et al.
STATISTICS IN MEDICINE (2015)
INDEPENDENT RADIOLOGICAL EVALUATION OF OBJECTIVE RESPONSE, EARLY TUMOR SHRINKAGE, AND DEPTH OF RESPONSE IN FIRE-3 (AIO KRK-0306) IN THE FINAL RAS EVALUABLE POPULATION
S. Stintzing et al.
ANNALS OF ONCOLOGY (2014)
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann et al.
LANCET ONCOLOGY (2014)
Early tumor shrinkage in metastatic colorectal cancer: Retrospective analysis from an irinotecan-based randomized first-line trial
Clemens Giessen et al.
CANCER SCIENCE (2013)
Size determination and response assessment of liver metastases with computed tomography-Comparison of RECIST and volumetric algorithms
Jan Holger Rothe et al.
EUROPEAN JOURNAL OF RADIOLOGY (2013)
Volumetric response classification in metastatic solid tumors on MSCT: Initial results in a whole-body setting
A. M. Wulff et al.
EUROPEAN JOURNAL OF RADIOLOGY (2013)
Use of Early Tumor Shrinkage to Predict Long-Term Outcome in Metastatic Colorectal Cancer Treated With Cetuximab
Hubert Piessevaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Jean-Yves Douillard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy
C. Suzuki et al.
ANNALS OF ONCOLOGY (2012)
A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development
Binsheng Zhao et al.
CLINICAL CANCER RESEARCH (2010)
Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial)
H. Piessevaux et al.
ANNALS OF ONCOLOGY (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
W. De Roock et al.
ANNALS OF ONCOLOGY (2008)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
分享论文
